ClinicalTrials.Veeva

Menu
C

Consultants in Neurology, Ltd. | Northbrook, IL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Satralizumab
Frexalimab
SAR441344
LY3541860
IMU-838
Ocrelizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 8 total trials

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and...

Enrolling
Multiple Sclerosis
Drug: LY3541860
Drug: Placebo

The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occur...

Enrolling
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Other: Placebo
Drug: Satralizumab

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...

Enrolling
Multiple Sclerosis
Drug: Activated charcoal
Drug: Cholestyramine

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling
Multiple Sclerosis
Drug: Frexalimab
Drug: Placebo

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have particip...

Enrolling
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressiv...

Active, not recruiting
Multiple Sclerosis
Drug: Placebo matching IMU-838
Drug: IMU-838

Trial sponsors

Roche logo
Sanofi logo
I
Lilly logo
Novartis logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems